Resource Library

The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics…

As everyone in the field is aware, the NIH conducted an input process last year that concluded with a release of new HIV prevention research priorities that favor long acting, systemic formulations (like vaccines, implants and injectables) and negate the need for short acting, user-controlled,…

Uganda has experienced cases of tetanus in the safe male circumcision (SMC) program for HIV prevention. Gulu district begun implementation of tetanus toxoid (TT) vaccination of men prior to SMC in 2015. However, there is concern that the introduction of the vaccine in SMC may lead to reduced…

Data on carcinogenicity of human papillomavirus (HPV) types in the anus are needed to inform anal cancer prevention through vaccination and screening. This is particularly the case for people infected with HIV, who are at an increased risk of anal cancer.

Integrated, multidisciplinary responses are increasingly critical from economic, political and health systems perspectives; piecemeal approaches leave too many gaps in the elements left unaddressed. A strengthened focus on SRHR/HIV integrated healthcare service delivery can support the…

The HIV pandemic continues to impose enormous morbidity, mortality, and economic burdens across the globe. Simultaneously, innovations in antiretroviral therapy, diagnostic approaches, and vaccine development are providing novel tools for treatment-as-prevention and prophylaxis. We developed a…

A quick, colorful and comprehensive overview of HIV vaccine research. Four pages, five top-line updates, this is a speedy read, designed to give a sense of the momentum and major issues coming up in the year to come.

The development of immunologic interventions that can target the viral reservoir in HIV-1-infected individuals is a major goal of the HIV-1 cure field. However, little evidence exists that the viral reservoir can be sufficiently targeted to improve virologic control following discontinuation of…

The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention and treatment of HIV infection. We sought to determine whether passive administration of VRC01, a bNAb targeting…

Although the risk of human papillomavirus (HPV) infection is greatest in young women, women older than 25 years remain at risk. We present data from the VIVIANE study of the HPV 16/18 AS04-adjuvanted vaccine in adult women after 7 years of follow-up.

A major obstacle to a broadly neutralizing antibody (bnAb)-based HIV vaccine is the activation of appropriate B cell precursors. Germline-targeting immunogens must be capable of priming rare bnAb precursors in the physiological setting. We tested the ability of the VRC01-class bnAb germline-…

What have scientists learned that helped inform the design of this pivotal AIDS vaccine study in South Africa?

Seven years ago, a large efficacy trial in Thailand known as RV144 provided the first—and thus far only—clinical evidence of vaccine-induced protection against…

Vaccine costs in the developing world have grown from

The Expanded Program of Immunization (EPI) led by WHO and UNICEF has recently celebrated its 40th anniversary and the profound increase of childhood vaccination coverage globally to more than 80%. However, translation of this achievement into an estimate of deaths averted is daunting because of…

The Global Vaccine Action Plan (GVAP) ― endorsed by the 194 Member States of the World Health Assembly in May 2012 ― is a framework to prevent millions of deaths by 2020 through more equitable access to existing vaccines for people in all communities.

GVAP aims to strengthen routine…

In the last 15 years, antiretroviral therapy (ART) has been the most globally impactful life-saving development of medical research. Antiretrovirals (ARVs) are used with great success for both the treatment and prevention of HIV infection. Despite these remarkable advances, this epidemic grows…

The Vision for Health Systems Strengthening (HSS) 2015-2019 is a key document that will help guide USAID’s work and investment focus to evidence-based HSS approaches that contribute to positive health outcomes and help create an environment for universal health coverage. It will also help the…

A recent experimental HIV vaccine protected 50% of a group of twelve rhesus monkeys from infection by Simian Immunodeficiency Virus (SIV). Furthermore it did so by providing so-called ‘sterilising immunity’, meaning that it completely prevented infection in these monkeys rather than offering the…

Dr. Anthony Fauci, director of NIAID, delivered an opening keynote address at the Keystone Symposia on “HIV Vaccines” and “The Golden Anniversary of B Cell Discovery”. In his address, he summarizes why HIV vaccine development is different from other diseases, scientific approaches taken in…

This is an updated introductory two-page document that defines AIDS vaccines and reviews key developments in the field.